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In Taiwan, despite a substantial decline of Salmonella 
enterica serotype Choleraesuis infections, strains resistant 
to ciproﬂ  oxacin and ceftriaxone persist. A self-transferable 
blaCMY-2-harboring IncI1 plasmid was identiﬁ  ed  in  S. 
enterica serotypes Choleraesuis, Typhimurium, Agona, 
and Enteritidis and contributed to the overall increase of 
ceftriaxone resistance in salmonellae.
S
almonella enterica serotype Choleraesuis usually 
causes invasive infection (1). When resistant 
Salmonella infection is encountered, ﬂ  uoroquinolones or 
extended-spectrum cephalosporins are frequently used 
(2). Fluoroquinolone resistance has been common in this 
invasive serotype (3). Isolation of SC-B67, a strain of S. 
enterica ser. Choleraesuis that was resistant to ciproﬂ  oxacin 
and ceftriaxone (CIPr/CROr), has exacerbated the problem 
(4). Ceftriaxone resistance in SC-B67 was attributed to a 
plasmid-mediated blaCMY-2, located on a speciﬁ  c ISEcp1-
blaCMY-2-blc-sugE structure (4). This conserved DNA 
fragment, subsequently named Tn6092 ( 5), has been 
reported from different geographic areas and is widely 
distributed among various Salmonella serotypes and other 
Enterobacteriaceae (6).
The Study
Since 1999, computerized records of bacterial 
culture results have been stored at Chang Gung Memorial 
Hospital, a 3,500-bed medical center in northern Taiwan. 
Periodic review of these records indicated a reverse 
trend in the prevalence of serogroups D (increase) and B 
(decrease) isolates during the past decade (Figure 1, panel 
A). A signiﬁ  cant decrease in the prevalence of S. enterica 
ser. Choleraesuis was also evident (Figure 1, panel A). 
Nevertheless, in recent years, ceftriaxone resistance has 
increased from <5% to >10% in S. enterica ser. Choleraesuis 
and in serogroup B salmonellae (Figure 1, panel B).
Since isolation of SC-B67 in 2002 (4), 10 CIPr/CROr 
S. enterica ser. Choleraesuis isolates have been recovered. 
All CIPr/CROr isolates were resistant to nalidixic acid 
and ciproﬂ  oxacin, but SC-B134 remained susceptible to 
ciproﬂ  oxacin (Table 1). PCR and sequencing with speciﬁ  c 
primers (online Technical Appendix Table 1, www.cdc.gov/
EID/content/17/6/1086-Techapp.pdf) revealed 3 identical 
amino acid changes in GyrA and ParC among all CIPr/CROr 
isolates except SC-B134 (Table 1). Reduced ﬂ  uoroquinolone 
susceptibility of SC-B134 could be explained by the single 
amino acid change at codon 87 of GyrA. Amino acid 
changes were not found in GyrB or ParE.
In terms of clinical features (online Technical 
Appendix Table 2), most patients with these infections were 
adults who had a wide spectrum of underlying diseases. 
Antimicrobial agents were prescribed for all patients, 
and extended-spectrum cephalosporins were used most 
frequently. Two patients died. Seven blood isolates from 
the 10 patients with CIPr/CROr S. enterica ser. Choleraesuis 
infections, together with the ceftriaxone-resistant isolates 
noted below, were investigated further. SC-B67 was used 
as a reference.
During the ﬁ  rst 6 months of 2010, a total of 6 cases 
of ceftriaxone-resistant Salmonella infection were found: 
serogroup B in 5 patients (S. enterica ser. Agona, n = 1; S. 
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Figure 1. Secular trends in annual numbers (A) and rates (B) of 
ceftriaxone resistance among various serogroups or serotype of 
nontyphoidal Salmonella enterica isolates in Chang Gung Memorial 
Hospital, 1999–2010.Increasing Ceftriaxone Resistance in Salmonellae, Taiwan
enterica ser. Typhimurium, n = 4, including 1 Copenhagen 
variant) and serogroup D (S. enterica ser. Enteritidis) in 
1 patient (Table 1). All isolates were derived from fecal 
specimens of patients <3 years of age, except S. enterica 
ser. Typhimurium SB-28, which was isolated from the 
urine of a 77-year-old patient. In contrast to S. enterica ser. 
Choleraesuis, these ceftriaxone-resistant isolates generally 
remained susceptible to ﬂ  uoroquinolones (Table 1).
Pulsed-ﬁ   eld gel electrophoresis performed as 
described showed close association among all S. enterica 
ser. Choleraesuis isolates, including SC-B67 (Table 1; 
Figure 2, panel A) (7). Only strain SC-B136, recovered 
in 2008, demonstrated a relatively different pattern. Two 
pulsotypes, with minor differences, were found among the 
4 S. enterica ser. Typhimurium isolates (Table 1).
Ceftriaxone resistance was investigated by using PCR 
and sequencing as described (6). The speciﬁ  c  blaCMY-2-
carrying Tn6092 was present in all isolates tested (Table 
1). Tn6092 was located within a ﬁ  nQ gene at a position 
identical to that in SC-B67. The only difference was in SC-
B134; a 1,338-bp insertion sequence, IS10, was inserted 
262 bp upstream of the blaCMY-2. No CTX-M and SHV 
genes were found in these isolates.
Using an alkaline lysis method (8), we found various 
numbers of plasmids among the isolates studied (Table 
1). DNA–DNA hybridization indicated that Tn6092 was 
located on large (85-kb to 150-kb) plasmids (Table 1) 
(9). An identical Rep_3 replicon was found in all CIPr/
CROr S. enterica ser. Choleraesuis isolates studied (5). 
Similar to SC-B67, the Rep_3 replicon was located on the 
Tn6092-harboring resistance plasmid in the 5 resistant 
isolates recovered before 2004 (Table 1). However, in 
SC-B134, the Rep_3 replicon was found on the smaller 
40-kb plasmid, and in SC-B136, the Rep_3 replicon was 
on the 115-kb large virulence plasmid that contained the 
spvC gene (Table 1; Figure 2, panels B, C). Replicons 
FIIA and FIB were simultaneously present in all the spvC-
containing virulence plasmids among the S. enterica 
ser. Choleraesuis isolates studied (Table 1). Virulence 
plasmids in the 2 recent isolates, SC-B134 and SC-B136, 
appeared larger than those in earlier isolates, including 
SC-B67 (Table 1; Figure 2, panels B, C). The 2 bands 
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Table 1. Characteristics of the resistant Salmonella enterica isolates from 17 patients at Chang Gung Memorial Hospital, Taiwan* 
Serotype and 
isolate (no. 
patients) Year 
Type of 
specimen
Susceptibility 
profile† Puls‡
Plasmid
profile,
kb§
DNA–DNA hybridization¶  PCR sequencing# 
spvC
rep
FIIA/FIB Rep_3 
gyrA parC
Ser(83) D(87) Ser(80)
Choleraesuis
 SC-B67  2002  Blood R/R/R  C-1-a  50, 138 50 50 138 F N I
 SC-B104  (1)  2003  Blood R/R/R  C-1-b  50, 150 50 50 150 F N I
 SC-B93  (2)  2003  Blood R/R/R  C-1-b  50, 115 50 50 50,115 F N I
 SC-B98  (3)  2004  Blood R/R/R  C-1-c  50, 138 50 50 138 F N I
 NA  (4)  2004  Pus R/R/R  NA NA NA NA NA NA NA NA
 SC-B131  (5)  2004  Blood R/R/R  C-1-d  50, 138 50 50 138 F N I
 SC-B132  (6)  2004  Blood R/R/R  C-1-b  50, 150 50 50 150 F N I
 NA  (7)  2005  Pus R/S/R  NA NA NA NA NA NA NA NA
  SC-B134 (8)  2007  Blood R/S/R†  C-1-e  40, 65, 
105
65 65 40 Ser N Ser
 SC-B136  (9)  2008  Blood R/R/R  C-2  115, 138 115 115 115 F N I
 NA  (10)  2009  Pus R/S/R  NA NA NA NA NA NA NA NA
Typhimurium var. 
Copenhagen SB-5 
2010 Feces R/R/R  B-1-a 7, 125,
180, 260 
Neg Neg Neg  Ser D Ser
Typhimurium 
 SB-28  2010  Urine  R/R/S  B-2 115, 210  Neg  Neg  Neg  Ser D Ser
 SB-151  2010  Feces S/S/S B-1-b  85 Neg Neg Neg  Ser D Ser
 SB-193  2010  Feces R/R/S  B-2 105, 210  Neg  Neg  Neg  Ser D Ser
Agona SB-105  2010  Feces R/S/S B-3 95 Neg Neg Neg  Ser D Ser
Enteritidis SD-166  2010  Feces R/S/S D-1  45, 60, 
95
60 Neg Neg  Ser D Ser
*Puls, pulsotype; R, resistant; F, phenylalanine; N, asparagine; I, isoleucine; NA, not available; S, susceptible; ser, serine; neg, negative reaction; var., 
variant; D, aspartic acid. 
†Antimicrobial drug susceptibility to chloramphenicol, trimethoprim/sulfamethoxazole, and quinolones. Results were the same for the 2 quinolones 
(nalidixic acid and ciprofloxacin) tested, except that SC-B134 was resistant to nalidixic acid and susceptible to ciprofloxacin. All isolates were resistant to 
ampicillin and ceftriaxone. 
‡Pulsed-field gel electrophoresis; pulsotypes are expressed as serogroup-major type-subtype. 
§Plasmids harboring the blaCMY-2-carrying Tn6092 element are shown in boldface. IncI1 plasmids are underlined. Both are evidenced by DNA–DNA 
hybridization. 
¶The size (kb) of the plasmid showing positive results in the respective DNA–DNA hybridization experiments is indicated. Rep_3, replicon of pSC138, the 
Tn6092-containing resistant plasmid of strain SC-B67.  
#Amino acid changes compared with the quinolone resistance–determining regions of gyrA (codons 83 and 87) and parC (codon 80) in S. enterica
serotype Typhimurium LT2. No mutation was found in gyrB and parE.demonstrated by the spvC probe in SC-B134 were 
from the same single virulence plasmid, as proven by 
hybridization experiments on BamHI-digested plasmid 
DNA of SC-B134 (data not shown).
Replicon typing through a published multiplex 
PCR system revealed a replicon I1 from the Tn6092-
harboring resistance plasmids in SC-B134 and SC-B136 
(Table 1; Figure 2, panel C) (10). Similarly, Tn6092-
carrying plasmids among the other ceftriaxone-resistant 
salmonellae isolates all belonged to the IncI1 group 
(Table 1). Conjugation experiments using a ﬁ  lter mating 
method showed that all IncI1 resistant plasmids were self-
transferrable (11). With azide-resistant Escherichia coli 
J53 and S. enterica ser. Typhimurium LBNP4417 as the 
recipients, the IncI1-resistant plasmids were conﬁ  rmed to 
be self-transferrable.
Subtyping of the 8 conjugated IncI1 plasmids was 
achieved by using a recently described plasmid multilocus 
sequence typing (pMLST) method speciﬁ  cally set up for 
IncI1 plasmids (12). Six combinations of allele variants 
were obtained (Table 2). Because these pMLST patterns 
differed from those reported elsewhere, 6 new sequence 
types (STs) were designated (Table 2). Two major groups 
were further derived: ST54 (pSB28, pSB193) and ST52 
(pSC-B136) that differed only in trbA, and ST56 (pSD166, 
PSB105) and ST53 (pSB5) that only differed in pilL (Table 
2). pMLST patterns of representative blaCMY-2-carrying 
IncI1 plasmids published in recent years (Table 2) were 
derived from E. coli or various Salmonella serotypes in 
Europe or North America (12–14). Nine STs and 2 major 
clonal complexes, CC-2 and CC-12, were observed. 
pMLST patterns found in the present study differed from 
these STs by at least 3 alleles (Table 2).
Conclusions
Resistance to ciproﬂ  oxacin and ceftriaxone remains 
high, indicating persistence of antimicrobial drug–resistant 
traits in S. enterica ser. Choleraesuis. The conserved 
genotypes found in the clinical isolates suggest a mode 
of clonal dissemination. However, plasmid analysis 
indicates that the location of the Tn6092-containing 
resistance element had shifted from the nonconjugative 
Rep_3 plasmids in early isolates to the self-transferable 
IncI1 plasmids in recent isolates. The emergence of such 
self-transferable resistance plasmids seems to provide an 
efﬁ  cient way for S. enterica ser. Choleraesuis to spread its 
ceftriaxone resistance trait.
Because infections with nontyphoid salmonellae are 
rampant in Asia, emergence of a conjugative IncI1 resistance 
plasmid in ceftriaxone-resistant salmonellae from an Asian 
country is of public health concern. Presence of blaCMY-2-
carrying IncI1 plasmids in a variety of Salmonella serotypes 
has been reported, but to our knowledge, not in S. enterica 
serotypes Enteritidis or Choleraesuis (12–14). IncI1 plasmids 
of the same or similar STs have been found in isolates of 
different bacterial species; with different resistance genes; 
or from different countries or sources, including human, 
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Figure 2. Analyses of Salmonella enterica serotype Choleraesuis 
isolates from Chang Gung Memorial Hospital, 1999–2010. A) 
Pulsed-ﬁ   eld gel electrophoresis patterns. Lanes 1 and 10, DNA 
size markers demonstrated by a λ DNA concatemer standard and 
S. enterica ser. Braenderup H9812, respectively; lanes 2 to 9, S. 
enterica ser. Choleraesuis SC-B67, SC-B104, SC-B93, SC-B98, 
SC-B131, SC-B132, SC-B134, and SC-B136. B) Plasmid analysis 
and C) DNA–DNA hybridization. Probes for DNA–DNA hybridization 
of lanes 1–6, 7–12, and 13–16 were prepared from amplicons of 
spvC, Rep_3 replicon of pSC138 in SC-B67, and repI1, respectively; 
lanes 1 and 7, S. enterica ser. Choleraesuis OU7529 containing 2 
plasmids of known sizes, 50 kb and 90 kb, was used as the size 
marker; lanes 2 and 8, SC-B67; lanes 3, 9, and 13, SC-B134; lanes 
4, 10, and 14, SC-B136; lanes 5, 11, and 15, Escherichia coli J53/
pSC-B134; lanes 6, 12, and 16, E. coli J53/pSC-B136.Increasing Ceftriaxone Resistance in Salmonellae, Taiwan
animals, and the environment (12–15). Emergence of the 
IncI1 plasmid in Taiwan represents a need for continuous 
efforts to monitor and control its further spread.
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Table 2. Characteristics of conjugative blaCMY-2-harboring IncI1 plasmids derived in this study and comparison of pMLST patterns with 
similar plasmids published previously* 
IncI1
plasmid 
Salmonella enterica
serotype or
Escherichia coli
Susceptibility 
profile† Country
Year of 
isolation
pMLST‡ 
ST§ 
Clonal
complex Reference repI1 ardA trbA sogS pilL
pSC-B134 Choleraesuis R/S/S Taiwan  2007 1 1 15 9 3 51 NA This  study
pSC-B136 Choleraesuis R/R/S Taiwan  2008 1 4 15 11 2 52 NA This  study
pSB-5 Typhimurium 
variant Copenhagen 
R/R/R Taiwan  2010 2 1 15 11 2 53 NA This  study
pSB28 Typhimurium S/S/S Taiwan  2010  1 4 5 11 2 54 NA This  study
pSB151 Typhimurium S/S/S Taiwan  2010  4 5 15 11 3 55 NA This  study
pSB193 Typhimurium S/S/S Taiwan  2010  1 4 5 11 2 54 NA This  study
pSB105 Agona R/S/S Taiwan  2010  2 1 15 11 3 56 NA This  study
pSD166 Enteritidis R/S/S Taiwan  2010  2 1 15 11 3 56 NA This  study
398T  E. coli NA Italy 2006 1 2 3 2 1 2 CC-2  (12)
05–1909 Heidelberg  NA Canada 2005  123212C C - 2  ( 13)
1358T Thompson  NA USA 1996  1 3 3 4 1 4 CC-12  (12)
DH-20406 Heidelberg  NA USA 2004  143411 2 C C - 1 2  ( 14)
06–3048 4,5,12:i:–  NA Canada 2006  143411 2 C C - 1 2  ( 13)
06–3539 Agona  NA Canada 2006  143411 2 C C - 1 2  ( 13)
N07–0084  E. coli NA Canada 2005 1 4 3 4 1 12 CC-12  (13)
05–2835 Heidelberg  NA Canada 2005  1 4 3 4 1 12 CC-12  (13)
06–3985 Litchfield  NA Canada 2006  1 4 3 4 1 12 CC-12  (13)
05–5567 Typhimurium  NA Canada 2005  143411 2 C C - 1 2  ( 13)
N06–523  E. coli NA Canada 2006 1 4 3 2 1 18 CC-2/
CC-12 
(13)
N06–0537  E. coli NA Canada 2006 1 3 3 4 3 19 CC-12  (13)
05–6117 4,5,12:1:–  NA Canada 2006  113912 0 N A ( 13)
N07–0093  E. coli NA Canada 2005 1 1 3 9 1 20 NA (13)
06–0753 Heidelberg  NA Canada 2006  1 2 11 3 3 21 CC-5  (13)
N07–0079  E. coli NA Canada 2005 1 6 3 4 1 22 CC-12  (13)
N07–0081  E. coli NA Canada 2005 1 2 3 1 1 23 CC-2  (13)
*pMLST, plasmid multilocus sequence typing; ST, sequence type; R, resistant; S, susceptible; NA, not applicable. 
†Antimicrobial drug susceptibility to chloramphenicol, trimethoprim/sulfamethoxazole, and quinolones (nalidixic acid and ciprofloxacin). The 
transconjugants were also resistant to ampicillin and ceftriaxone. 
‡pMLST results were compared to those published in the plasmid MLST website (http://pubmlst.org/plasmid).  
§STs were designated according to the different combinations of allele variants observed among the IncI1 plasmids. 10.   Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 
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